Johnson & Johnson announced new 48-week data from the Phase III ASTRO study evaluating Tremfya (guselkumab) subcutaneous (SC) induction and maintenance therapy in adults with moderately to severely… read more.
A nationwide, longitudinal study characterized how physician attrition rates from clinical practice have changed and the factors associated with a differential likelihood of attrition. The study found that… read more.
Calorie labelling, which became law in April 2022 in England, is associated with only a small (2%) average reduction in the energy content of food that is available… read more.
Regeneron Pharmaceuticals, Inc. announced that the FDA has approved Evkeeza (evinacumab-dgnb) ANGPTL3 antibody as an adjunct to diet and exercise and other lipid-lowering therapies for the treatment of… read more.
Response times for emergency medical services (EMS) in rural areas can take almost 20 minutes longer compared to the national average, and the severity of the medical needs… read more.
The strong opioid painkiller, tramadol, is not that effective at easing chronic pain for which it’s widely prescribed, finds a pooled data analysis of the available research, published… read more.
At the European Society for Medical Oncology (ESMO) Congress 2025, Boehringer Ingelheim will present new data from across its robust oncology pipeline, including non-small cell lung cancer (NSCLC)… read more.
NICE (UK) – Garadacimab can be used as an option to prevent recurrent attacks of hereditary angioedema in people 12 years and over, only if: i) they have… read more.
Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one third of the adult population. This disorder is characterized by the… read more.
International Plasma Awareness Week (IPAW) takes place globally from October 6-10. The week encourages communities around the world to recognize the vital role of plasma in creating lifesaving… read more.
Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced that nine presentations related to Peyronie’s disease, or PD, and XIAFLEX® (collagenase clostridium histolyticum, injection 0.9 mg) will be shared… read more.
Neurocrine Biosciences, Inc. presented new data from the open-label KINECT-HD2 study demonstrating an established long-term safety profile, tolerability and sustained improvements in chorea severity through three years of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
